Deal Tracker · Countries
Oman pharma deals
20 pharma deals involving Oman — companies based there or deals covering the market — tracked by EPT: distribution, investment & partnerships. Most active: Khazaen Economic City, Taiba Healthcare, Dhofar Pharmaceutical Industries & JCR Pharmaceuticals. Latest: Emmaus Life Sciences → Al Wataniya Aldawliya (Distribution, 12 Nov 2026).
- EPT has tracked 20 Oman pharma deals (2022–2026), 16 of them announced in 2026.
- The most common structures are distribution (25%), investment (25%) & partnerships (20%).
- Values were disclosed for 6 of 20 deals, totalling $234m; the largest is Daewoong Pharmaceutical → Arcera Life Sciences ($94m, 29 Jun 2026).
- The most active companies: Khazaen Economic City (3), Taiba Healthcare (3), Dhofar Pharmaceutical Industries (2) & JCR Pharmaceuticals (2).
- Emmaus Life Sciences → Al Wataniya AldawliyaDistribution · MENA · Undisclosed · 12 Nov 2026
- Oman Investment Authority → Oryx IsotopesJoint venture · GCC · $17m · 8 Nov 2026
- Aram Pharma → Salalah Free ZoneEquity / Investment · GCC · Undisclosed · 1 Nov 2026
- Al Badr Trading & Industry, Lamaa Pharma, Al Mansoor + 1 other → Khazaen Economic CityEquity / Investment · GCC · $52m · 1 Nov 2026
- Rem3dy Health → Hikma PharmaceuticalsDistribution · GCC · Undisclosed · 29 Oct 2026
- Avenzo Pharma → Khazaen Economic CityEquity / Investment · GCC · Undisclosed · 14 Oct 2026
- JCR Pharmaceuticals → Taiba HealthcareDistribution · GCC · 14 Oct 2026
- Philex Pharmaceuticals → BiocareTechnology transfer / Localization · Africa · 11 Oct 2026
- Sana Pharma → National Pharmaceutical IndustriesPartnership / Collaboration · GCC · 8 Oct 2026
- Dhofar Pharmaceutical Industries → Philex PharmaceuticalsPartnership / Collaboration · GCC · 8 Oct 2026
- Dhofar Pharmaceutical Industries → Hydrogen Oncology PharmaceuticalsTechnology transfer / Localization · MENA · 8 Oct 2026
- Alfasigma → Nordic PharmaM&A / Acquisition · Global ex-US · See terms · 9 Aug 2026
- JCR Pharmaceuticals → Taiba HealthcareDistribution · MENA · Undisclosed · 21 Jul 2026
- Daewoong Pharmaceutical → Arcera Life SciencesLicensing · MENA · $94m · 29 Jun 2026
- Chemo & Olpha → CCL PharmaceuticalsSupply / Manufacturing · GCC · Undisclosed · 28 Jan 2026
- Gulf Pharmaceutical Industries and Medical Devices → Khazaen Economic CityEquity / Investment · GCC · $39m · 14 Jan 2026
- IMGSA → Omani InvestmentPartnership / Collaboration · GCC · $20m · 3 Nov 2025
- EQL Pharma → PharmalinkDistribution · GCC · See terms · 11 Mar 2025
- Immuneel Therapeutics → Taiba HealthcareEquity / Investment · MENA · $12m · 30 Jul 2024
- Huadong Medicine → JulpharPartnership / Collaboration · MENA · Undisclosed · 25 Jun 2022
Most active companies
Khazaen Economic City (3) · Taiba Healthcare (3) · Dhofar Pharmaceutical Industries (2) · JCR Pharmaceuticals (2) · Philex Pharmaceuticals (2)
Largest disclosed deals
- Daewoong Pharmaceutical → Arcera Life Sciences · $94m · Licensing · 29 Jun 2026
- Al Badr Trading & Industry, Lamaa Pharma, Al Mansoor + 1 other → Khazaen Economic City · $52m · Equity / Investment · 1 Nov 2026
- Gulf Pharmaceutical Industries and Medical Devices → Khazaen Economic City · $39m · Equity / Investment · 14 Jan 2026
Questions
- How many Oman pharma deals has EPT tracked?
- 20 as of 12 Nov 2026, covering 2022–2026; 16 were announced in 2026. The most recent is Emmaus Life Sciences → Al Wataniya Aldawliya (Distribution, 12 Nov 2026).
- What types of Oman pharma deals are most common?
- Distribution: 5 (25%); Equity / Investment: 5 (25%); Partnership / Collaboration: 4 (20%); Technology transfer / Localization: 2 (10%).
- Which companies are most active in Oman pharma deals?
- Khazaen Economic City (3 deals), Taiba Healthcare (3 deals), Dhofar Pharmaceutical Industries (2 deals), JCR Pharmaceuticals (2 deals), Philex Pharmaceuticals (2 deals).
- What is the largest disclosed Oman pharma deal?
- Daewoong Pharmaceutical → Arcera Life Sciences: $94m (Licensing, 29 Jun 2026); Al Badr Trading & Industry, Lamaa Pharma, Al Mansoor + 1 other → Khazaen Economic City: $52m (Equity / Investment, 1 Nov 2026); Gulf Pharmaceutical Industries and Medical Devices → Khazaen Economic City: $39m (Equity / Investment, 14 Jan 2026). Values are as announced by the parties.
Browse deals
By region
GCC (83) · MENA (66) · Africa (17) · Latin America (17) · Southeast Asia (17) · Global (LMICs) (14) · CIS & Central Asia (13) · Türkiye (5) · Global ex-US (1)
By country
Saudi Arabia (69) · UAE (61) · China (31) · Egypt (27) · United States (26) · India (19) · Switzerland (18) · Jordan (14) · South Korea (14) · Kazakhstan (13) · Algeria (12) · Türkiye (12) · United Kingdom (11) · Brazil (10) · Kuwait (10) · Iraq (8) · Morocco (8) · Bahrain (7) · Malaysia (7) · Spain (7) · Argentina (6) · Germany (6) · Indonesia (6) · Philippines (6) · Qatar (6) · Italy (5) · Mexico (5) · Vietnam (5) · France (4) · Taiwan (4) · Tunisia (4) · Canada (3) · Chile (3) · Denmark (3) · Greece (3) · Japan (3) · Lebanon (3) · Nigeria (3) · Pakistan (3) · South Africa (3) · Sweden (3) · Thailand (3) · Azerbaijan (2) · Colombia (2) · Ireland (2) · Kenya (2) · Libya (2) · Netherlands (2) · Singapore (2) · Uruguay (2) · Uzbekistan (2)
By deal type
Licensing (56) · Distribution (41) · Technology transfer / Localization (39) · Partnership / Collaboration (35) · M&A / Acquisition (21) · Equity / Investment (18) · Joint venture (11) · Supply / Manufacturing (10)
Popular searches
MENA pharma licensing deals (25) · Saudi Arabia pharma licensing deals (24) · GCC pharma distribution deals (21) · GCC pharma partnerships (19) · China pharma licensing deals (17) · UAE pharma distribution deals (17) · GCC pharma localization & tech-transfer deals (15) · Saudi Arabia pharma distribution deals (14) · UAE pharma partnerships (13) · UAE pharma licensing deals (12) · Global (LMICs) pharma licensing deals (11) · India pharma licensing deals (11) · GCC pharma licensing deals (10) · MENA pharma partnerships (10) · Saudi Arabia pharma localization & tech-transfer deals (10) · MENA pharma localization & tech-transfer deals (9) · United States pharma licensing deals (9) · Egypt pharma localization & tech-transfer deals (8) · Saudi Arabia pharma partnerships (8) · CIS & Central Asia pharma localization & tech-transfer deals (7) · Kazakhstan pharma localization & tech-transfer deals (7) · MENA pharma distribution deals (7) · MENA pharma M&A deals (7) · United States pharma distribution deals (7)
By company
ADCAN Pharma (13) · Mubadala Bio (8) · Jamjoom Pharma (7) · SPIMACO (7) · Arcera Life Sciences (6) · Hikma Pharmaceuticals (6) · Bio-Thera Solutions (6) · Avalon Pharma (5) · Tabuk Pharmaceuticals (5) · Local Content and Government Procurement Authority (5) · Kazakhstan Ministry of Health (5) · Eva Pharma (4) · Sandoz (4) · Department of Health – Abu Dhabi (4) · Biocon (4) · Groupe Saidal (4) · Gilead Sciences (3) · Dr. Reddy's Laboratories (3) · Emirates Drug Establishment (3) · Novo Nordisk (3) · Khazaen Economic City (3) · Galenicum (3) · Roche (3) · Laprophan (3) · Sanofi (3) · Gen İlaç (3) · Taiba Healthcare (3) · Dar Al Dawa (3) · Lifera (3) · Celltrion (2) · Viatris (2) · Rem3dy Health (2) · AMA Medical Manufacturing (2) · Afreximbank (2) · M42 (2) · Abbott (2) · DKSH (2) · Adalvo (2) · Rameda (2) · Menarini (2) · Korea United Pharm (2) · Samsung Bioepis (2) · AstraZeneca (2) · MS Pharma (2) · LifePharma (2) · Duopharma Biotech (2) · JCR Pharmaceuticals (2) · Philex Pharmaceuticals (2) · Lotus Pharmaceutical (2) · Elpen (2) · Dhofar Pharmaceutical Industries (2) · Accord Healthcare (2) · CCL Pharmaceuticals (2) · Abdi İbrahim (2) · Nordic Pharma (2) · UNIMED Laboratories (2) · Minapharm (2) · SaudiVax (2) · Faes Farma (2) · AJA Pharma (2) · VACSERA (2) · Bayer (2) · Shanghai Henlius Biotech (2) · Julphar (2)
By therapeutic area
Multi-therapy (64) · Oncology (30) · Metabolic / Diabetes (27) · Cardiovascular (17) · Vaccines (15) · Immunology / Inflammation (13) · Rare / Orphan (9) · Infectious Disease (8) · CNS / Neurology (6) · Ophthalmology (6) · Consumer health (5) · Women's Health (4) · Respiratory (2)